Clinical Trial Update: Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008) [Phase 1]

View source ↗

Summary

Phase 1 trial assessing changes in hepatic fat after administration of MK-4074 with pioglitazone; completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• MK-4074 (MK-4074)
• Pioglitazone hydrochloride (Pioglitazone hydrochloride)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-alcoholic Fatty Liver Disease | Phase 1 | Status: COMPLETED | Results posted: 2016-03-25